Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Clot PF"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Clot PF; Translational Medicine and Early Development (TMED)/Clinical Pharmacology (TMCP) and Neuro and Neuro-Immunology, 371 Rue du Professeur Blayac, Sanofi, Montpellier, 34080, France. Pierre-Francois.Clot@sanofi.com., Farenc C; TMED Pharmacokinetics Dynamics and Metabolism, Sanofi, Montpellier, France., Suratt BT; Early Clinical Development Immunology and Inflammation, Sanofi, Cambridge, MA, United States of America., Krahnke T; CEP Germany, Sanofi Deutschland GmbH, Frankfurt, Germany., Tardat A; Early Development Operations, Sanofi, Montpellier, France., Florian P; Type 1/17 Immunology and Arthritis, Sanofi Deutschland GmbH, Frankfurt, Germany.; Head of Fibrotic Disease Research, Boehringer Ingelheim Vetmedica GmbH, Global AH Research, Ingelheim, Germany., Pomponio R; TMED Biomarkers and Clinical Bioanalysis, Sanofi, Framingham, MA, United States of America., Patel N; Global Development in Immunology and Inflammation, Sanofi, Cambridge, MA, United States of America., Wiekowski M; Immunology and Inflammation Development Franchise, Sanofi, Bridgewater, NJ, United States of America., Lin Y; Sanofi, Bridgewater, NJ, United States of America., Terrier B; Department of Internal Medicine, Cochin Hospital, Paris, France., Staudinger H; Immunology and Inflammation Development Franchise, Sanofi, Bridgewater, NJ, United States of America.
Publikováno v:
Respiratory research [Respir Res] 2024 Feb 28; Vol. 25 (1), pp. 107. Date of Electronic Publication: 2024 Feb 28.
Autor:
Clot PF; Sanofi, Paris, France., Kamal M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Sun J; Ruijin Hospital, Shanghai, China., Xu C; Sanofi, Bridgewater, NJ, USA., Kong F; Sanofi, Shanghai, China., Gu Y; Sanofi, Beijing, China., Yang N; Sanofi, Beijing, China., Yin W; Ruijin Hospital, Shanghai, China., Chen B; Ruijin Hospital, Shanghai, China., Ming JE; Sanofi, Bridgewater, NJ, USA., Yuan Y; Ruijin Hospital, Shanghai, China. Electronic address: yyz28@medmail.com.cn.
Publikováno v:
International immunopharmacology [Int Immunopharmacol] 2021 Oct; Vol. 99, pp. 107985. Date of Electronic Publication: 2021 Aug 12.
Autor:
Sarantopoulos J; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Mita AC; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA., He A; Department of Medicine and Oncology and Innovation Center for Biomedical Informatics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Wade JL; Division of Medical Oncology/Hematology, Cancer Care Center of Decatur, Decatur, IL, USA., Hsueh CT; Division of Medical Oncology/Hematology, Loma Linda University, Loma Linda, CA, USA., Morris JC; Division of Hematology-Oncology, Department of Medicine, University of Cincinnati Cancer Institute, Cincinnati, OH, USA., Lockhart AC; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA., Quinn DI; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Hwang J; Department of Medicine and Oncology and Innovation Center for Biomedical Informatics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Mier J; Department of Medicine, Dana-Farber/Harvard Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA., Zhang W; Sanofi, Bridgewater, NJ, USA., Wack C; Sanofi, Chilly-Mazarin, France., Yin J; Sanofi, Bridgewater, NJ, USA., Clot PF; Sanofi, Chilly-Mazarin, France., Rixe O; Division of Hematology/Oncology, Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA. ORixe@salud.unm.edu.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2017 Feb; Vol. 79 (2), pp. 339-351. Date of Electronic Publication: 2017 Jan 05.
Autor:
Azaro A; Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. aazaro@vhio.net.; Pharmacology Department, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. aazaro@vhio.net., Rodón J; Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Machiels JP; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium., Rottey S; Department of Medical Oncology, University Hospital of Ghent and Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium., Damian S; Department of Medical Oncology, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy., Baird R; Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK., Garcia-Corbacho J; Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK., Mathijssen RHJ; Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Clot PF; Sanofi, Chilly-Mazarin, France., Wack C; Sanofi, Chilly-Mazarin, France., Shen L; Sanofi, Bridgewater, NJ, USA., de Jonge MJA; Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Dec; Vol. 78 (6), pp. 1185-1197. Date of Electronic Publication: 2016 Oct 27.